Two from UK join Caligor Rx in US

Will lead quality assurance and clinical trial supplies

Caligor Rx, a global clinical trial procurement company based in New York, US, has appointed Jess McKenna as head of quality assurance and customer relationships and Jacquelyn May as head of clinical trial supplies. The two women join Caligor Rx, as a team, after having spent five years working together for a UK supplier of clinical trial supplies.

McKenna has a first class degree in Health and Social Care from the Open University in the UK. She was most recently responsible for building a quality assurance department at a supplier of comparator drugs.

May is a registered nurse and joins Caligor Rx after five years in comparator procurement for worldwide clinical trials. She was previously a senior manager in the NHS in the UK.

You may also like

Regulatory

Diversis Capital acquires Caligor Rx

Caligor sources and distributes comparator drugs for clinical trials worldwide from the US and UK
Regulatory

FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus

AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Britain's biotech potential (part I): world-class science, second-class support?

The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
Manufacturing

FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing

A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
Manufacturing

Precision meets innovation in melting point determination

Advancing analytical accuracy with automated thermal analysis
Subscribe now